Overview

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Status:
Withdrawn
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Phase II study to evaluate the efficacy and safety of DR vs R-CHOP in subjects with relapsed/refractory FL
Phase:
Phase 2
Details
Lead Sponsor:
Infinity Pharmaceuticals, Inc.
SecuraBio
Treatments:
Doxorubicin
Liposomal doxorubicin
Prednisone
Rituximab
Vincristine